Illustrative image – not actual.Shantha Biotechnics plans to invest Rs.120 crore to set up a multi-product manufacturing facility for genetically-engineered proteins in Hyderabad.
The facility will meet the requirements of FDA of the
US. The facility would cater to the European Union and the US markets.
The company also plans to set up research and development
centres at Chennai and Bangalore with an investment of Rs.40 – Rs.50 crore.
These centres would focus on biotechnological applications in healthcare.
The company is planning to come out with a Rs.200 –
Rs.250 crore public issue to finance its projects.
